BridgeBio Oncology Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

• BridgeBio Oncology Therapeutics Inc reported a quarterly adjusted loss of 43 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.03. The mean expectation of eleven analysts for the quarter was for a loss of 69 cents per share. Wall Street expected results to range from -80 cents to -59 cents per share.

• Reported revenue was zero​; analysts expected zero.

• BridgeBio Oncology Therapeutics Inc's reported EPS for the quarter was a loss of 43 cents​.

• The company reported a quarterly loss of $34.18 million.

• BridgeBio Oncology Therapeutics Inc shares had fallen by 43.9% this quarter and lost 81.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 11.3% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for BridgeBio Oncology Therapeutics Inc is $21.00, about 89% above its last closing price of $2.30

This summary was machine generated from LSEG data November 10 at 10:28 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)